From: Attitudes toward clinical trials across the Alzheimer’s disease spectrum
Trial design elements | Diagnostic group | Likelihood of participation | ||
---|---|---|---|---|
Very unlikely (score = 1–2) | Neutral (score = 3–5) | Very likely (score = 6–7) | ||
Approved | CN | 6 (16.2%) | 19 (51.4%) | 12 (32.4%) |
MCI | 2 (6.25%) | 12 (37.5%) | 18 (56.3%) | |
Dementia | 0 (0.00%) | 5 (22.7%) | 17 (77.3%) | |
Experimental | CN | 11 (29.7%) | 21 (56.8%) | 5 (13.5%) |
MCI | 4 (12.5%) | 17 (53.1%) | 11 (34.4%) | |
Dementia | 5 (22.7%) | 4 (18.2%) | 13 (59.1%) | |
Pill | CN | 7 (18.9%) | 21 (56.8%) | 9 (24.3%) |
MCI | 4 (12.5%) | 14 (43.8%) | 14 (43.8%) | |
Dementia | 4 (18.2%) | 3 (13.6%) | 15 (68.2%) | |
Infused | CN | 12 (32.4%) | 23 (62.2%) | 2 (5.4%) |
MCI | 9 (28.1%) | 17 (53.1%) | 6 (18.8%) | |
Dementia | 6 (27.3%) | 9 (40.9%) | 7 (31.8%) | |
Diet/exercise | CN | 4 (10.8%) | 18 (48.65%) | 15 (40.5%) |
MCI | 4 (12.5%) | 10 (31.3%) | 18 (56.3%) | |
Dementia | 3 (13.6%) | 8 (36.4%) | 11 (50.0%) | |
Supplement | CN | 4 (10.8%) | 13 (35.1%) | 20 (54.1%) |
MCI | 2 (6.3%) | 9 (28.1%) | 21 (65.6%) | |
Dementia | 2 (9.1%) | 8 (36.4%) | 12 (54.6%) | |
MRI | CN | 7 (18.9%) | 12 (32.4%) | 18 (48.7%) |
MCI | 7 (21.9%) | 8 (25.0%) | 17 (53.1%) | |
Dementia | 4 (18.2%) | 9 (40.9%) | 9 (40.9%) | |
PET scan | CN | 12 (32.4%) | 11 (29.7%) | 14 (37.8%) |
MCI | 8 (25.0%) | 9 (28.1%) | 15 (46.8%) | |
Dementia | 4 (18.2%) | 9 (40.9%) | 9 (40.9%) | |
Lumbar | CN | 24 (64.8%) | 12 (32.4%) | 1 (2.7%) |
punctures | MCI | 15 (46.9%) | 9 (28.1%) | 8 (25.0%) |
Dementia | 10 (45.4%) | 9 (40.9%) | 3 (13.6%) | |
Bleeding in brain or gut | CN | 30 (81.1%) | 6 (16.2%) | 1 (2.7%) |
MCI | 18 (56.3%) | 11 (34.4%) | 3 (9.4%) | |
Dementia | 10 (45.5%) | 9 (40.9%) | 3 (13.6%) | |
Headache or nausea | CN | 15 (40.5%) | 20 (54.1%) | 2 (5.4%) |
MCI | 9 (28.1%) | 16 (50.0%) | 7 (21.9%) | |
Dementia | 9 (40.9%) | 8 (36.4%) | 5 (22.7%) |